contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-health-seeking-commercial-recipe-success

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

I went to ask Teemu about news from the autumn and early winter on video  Merry Christmas to the thread!                    Inderes              Nightingale Health: Kaupalliset aihiot kehittyvät - Inderes    Aika: 22.12.2025 klo 21.13 Videolla Nightingale Healthin toimitusjohtaja Teemu Suna käy läpi yhtiön syksyn kuulumisia.

@Homeros This 2022 Nature article was not written by people working at NG. It was the 2023 Nature article. Additionally, it is sometimes forgotten in the discussion that a single test from NG does not measure the risk of developing one specific disease as an outcome, e.g., hypertension, but rather risk predictions are obtained for several common chronic diseases. From the strengths/limitations of the 2022 article’s discussion: In our perspective, 1H-NMR metabolomics profiling is an attractive candidate for a single-domain, multidisease assay. Because many countries already recommend regular check-ups entailing blood tests in the prevention of selected common diseases, our results indicate the potential of NMR metabolomic profiling in combination with simple demographic, but also with comprehensive laboratory predictors to estimate disease risk. In addition, metabolomic risk profiles could be of potential value in the guidance of pharmacological and lifestyle interventions. This is especially relevant for diseases such as T2D, where interventions on modifiable risk factors have been shown to delay disease onset and prevent subsequent comorbidities. Similarly, the Lancet 2020 commission suggested that up to 40% of worldwide dementia may be preventable by interventions on modifiable risk factors. This is particularly compelling because today’s pharmacological treatment options for dementia are scarce. However, the efficacy of various lifestyle interventions is disputed, calling for further experimental investigation. Before application in routine care, substantial challenges remain. While the 1H-NMR assay is robust and cheaper than mass-spectrometry-based alternatives, sensitivity is lower. Also, current metabolite coverage is relatively narrow and lipid focused. Although a future expansion of metabolite coverage is expected, it presents a limitation for clinical utility to date. Further, downstream quantification from raw NMR spectra needs to be harmonized for the reliable application of multivariable prediction models. While our study population is more healthy and less deprived than the general UK population, the results of external validation in four independent cohorts indicate general transferability of metabolomic states. However, the scope of validation was limited by the available endpoint information, constraining the replication to a subset of seven endpoints. In light of these limitations, we recommend careful scrutinization before application of the metabolomic state model beyond the validated conditions or in specific populations outside the research context. Ultimately, a broad rollout of NMR metabolomics for clinical care requires multiple logistical questions to be addressed, including both sample processing and transport.

Homeros clearly has an understanding of natural sciences, health economics, and medicine regarding the matter.

Neither of your claims is true: the cost-benefit ratio is not good, it is therefore completely unproven, and I don’t understand the time savings at all. In real life, NG does not work by a person putting their finger into an MRI machine and simultaneously receiving actionable and understandable instructions for changing their lifestyle. At a population level, a simple LDL cholesterol determination works better and cheaper than NG.

I don’t actually know anything; I’m only trying to discuss openly the research results that NG itself refers to. People here didn’t seem to know what NG’s own test ultimately costs the wellbeing services counties, let alone what the total cost is, because sampling costs and other indirect costs must be added when health economic efficiency is being calculated. But the price should definitely be pushed down from what is listed on Terveystalo’s website.  Roughly speaking, in Western countries, it is thought that in healthcare, one quality-adjusted life year (QALY) can cost a maximum of 20,000 - 50,000 euros. Cardiovascular events are associated with an average loss of 1.5 QALYs, so when 100,000 people are screened with the NMR risk model used in that study, thereby preventing 92 cardiac events, all the costs of the NMR blood analysis would have to be at most 30-70 euros for this screening to be just marginally cost-effective. The problem is the modest added benefit of measuring the metabolome. There seem to be better options, such as the old traditional labs in this case as well.  I wonder why this data isn’t put prominently on the front page if it shows that NG’s tests are extremely good and even cost-effective? The only hard data that has been published is that Nature article written by NG, where the peer reviewer stated that based on the results presented, the risk tests are not suitable for clinical use. This latest EHJ article gives a similar picture; the benefit is questionable.

Wouldn’t it make sense in Finland to test the entire population (adults) once a year, combined with a meeting (a nurse would suffice) for some hand-holding? The test would provide a solid basis for discussions on lifestyle changes etc. etc., even if Pera is unlikely to give up his sausage and beer or bother going for a jog. But people would always know to expect their “clinic visit” and would refrain from burdening the healthcare system in the meantime. It wouldn’t be any better or more effective care, but it would be billions cheaper than the current tinkering  We’re unlikely to see quick moves in Finland, but NH has opportunities in many other countries where change is seen as an opportunity.

True, that’s how it goes. What is the real price? Hardly that TT’s selling price, but I don’t believe that HVA gets it at the RRP (ovh) either.

Nightingale Health

Nightingale Health is a technology company built around blood analysis. The company tries with new technology, which initially seems competitive, to break into a conservative health care customer...

<p>Nightingale Health is a technology company built around blood analysis. The company tries with new technology, which initially seems competitive, to break into a conservative health care customer base, where achieving commercial success and its possible timing are, however, very uncertain. Despite the high long-term potential, we still have to wait for the signs of success and believe that positive share price drivers are still scarce. We, therefore, believe that the risk/return ratio will be weak over the next 12 months. </p> 

	2022	23e	24e
Revenue	2.3	4.3	5.2
growth-%	0.3 %	84.2 %	22.2 %
EBIT (adj.)	-13.6	-18.4	-17.8
EBIT-% (adj.)	-589.5 %	-431.1 %	-342.5 %
EPS (adj.)	-0.23	-0.30	-0.30
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	3.1	neg.	neg.

Nightingale Health: Seeking a commercial recipe for success

Login required

Key Estimate Figures05.06.2023

Forum discussions